Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DBT010
MIFTS: 59

Diabetic Neuropathy

Categories: Neuronal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Diabetic Neuropathy

About this section

MalaCards integrated aliases for Diabetic Neuropathy:

Name: Diabetic Neuropathy 38 12 76 54 37 15
Diabetic Neuropathies 55 73

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:9743
ICD9CM 35 250.6
MeSH 44 D003929
NCIt 50 C26748
KEGG 37 H01459
UMLS 73 C0011882
Sources

Summaries for Diabetic Neuropathy

About this section
NINDS : 54 Diabetic neuropathy is a peripheral nerve disorder caused by diabetes or poor blood sugar control. The most common types of diabetic neuropathy result in problems with sensation in the feet. It can develop slowly after many years of diabetes or may occur early in the disease. The symptoms are numbness, pain, or tingling in the feet or lower legs. The pain can be intense and require treatment to relieve the discomfort. The loss of sensation in the feet may also increase the possibility that foot injuries will go unnoticed and develop into ulcers or lesions that become infected. In some cases, diabetic neuropathy can be associated with difficulty walking and some weakness in the foot muscles. There are other types of diabetic-related neuropathies that affect specific parts of the body. For example, diabetic amyotrophy causes pain, weakness and wasting of the thigh muscles, or cranial nerve infarcts that may result in double vision, a drooping eyelid, or dizziness. Diabetes can also affect the autonomic nerves that control blood pressure, the digestive tract, bladder function, and sexual organs. Problems with the autonomic nerves may cause lightheadedness, indigestion, diarrhea or constipation, difficulty with bladder control, and impotence.

MalaCards based summary : Diabetic Neuropathy, also known as diabetic neuropathies, is related to microvascular complications of diabetes 5 and microvascular complications of diabetes 3, and has symptoms including neuralgia and sciatica. An important gene associated with Diabetic Neuropathy is AKR1B1 (Aldo-Keto Reductase Family 1 Member B), and among its related pathways/superpathways are AGE-RAGE signaling pathway in diabetic complications and PEDF Induced Signaling. The drugs Pregabalin and AT-101 have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 76 Diabetic neuropathies are nerve damaging disorders associated with diabetes mellitus. These conditions... more...

Sources

Related Diseases for Diabetic Neuropathy

About this section

Diseases related to Diabetic Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 131)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 5 32.2 ACE AKR1B1 INS VEGFA
2 microvascular complications of diabetes 3 32.1 ACE AKR1B1 INS
3 diabetic autonomic neuropathy 31.5 AKR1B1 EPO INS NGF NTF3
4 neuropathy 30.9 MPZ NGF PMP22 SCN9A
5 polyneuropathy 30.4 AKR1B1 MPZ PMP22
6 sleep apnea 30.4 ACE INS VEGFA
7 diabetes mellitus 30.0 ACE AKR1B1 EPO INS SOD2 VEGFA
8 arteries, anomalies of 29.9 ACE INS TRPV1 VEGFA
9 diabetic polyneuropathy 28.6 AKR1B1 NGF NTF3 SOD2 SOD3 VEGFA
10 autonomic neuropathy 28.5 AKR1B1 INS NGF NTRK1 SCN9A
11 peripheral nervous system disease 28.1 INS MPZ NGF PMP22 SCN9A TRPV1
12 amyotrophic lateral sclerosis 1 27.9 CNTF GDNF NGF NGFR SOD2
13 microvascular complications of diabetes 1 11.5
14 microvascular complications of diabetes 2 10.8
15 microvascular complications of diabetes 4 10.8
16 microvascular complications of diabetes 6 10.8
17 microvascular complications of diabetes 7 10.8
18 abducens nerve disease 10.8
19 argyll robertson pupil 10.8
20 fainting 10.8
21 syncope 10.8
22 hypertensive encephalopathy 10.7 ACE EPO
23 severe nonproliferative diabetic retinopathy 10.7 INS VEGFA
24 lesion of sciatic nerve 10.7 NGF TRPV1
25 renal artery disease 10.7 ACE EPO
26 neuropathy, hereditary sensory and autonomic, type v 10.6 NGF NTRK1
27 hereditary neuropathy with liability to pressure palsy 10.6 MPZ PMP22
28 congenital hypomyelination neuropathy 10.6 MPZ PMP22
29 charcot-marie-tooth neuropathy type 1 10.6 MPZ PMP22
30 retinal vascular disease 10.5 AKR1B1 INS VEGFA
31 mononeuritis of lower limb 10.5 PMP22 TRPV1
32 hypoglycemic coma 10.5 INS NTF3 VEGFA
33 foot drop 10.5 MPZ PMP22
34 roussy-levy hereditary areflexic dystasia 10.5 MPZ PMP22
35 immune system disease 10.5 ACE EPO TRPV1
36 cough variant asthma 10.5 NGF TRPV1
37 female reproductive system disease 10.4 INS TRPV1 VEGFA
38 charcot-marie-tooth disease, demyelinating, type 1f 10.4 MPZ PMP22
39 askin's tumor 10.4 NGF NTRK1
40 glucose metabolism disease 10.4 ACE INS TRPV1
41 charcot-marie-tooth disease, demyelinating, type 1c 10.4 MPZ PMP22
42 prurigo nodularis 10.4 NGF NGFR
43 acquired metabolic disease 10.4 ACE INS TRPV1
44 sick building syndrome 10.3 TRPV1 VEGFA
45 charcot-marie-tooth disease, demyelinating, type 1a 10.3 MPZ NTF3 PMP22
46 tetraploidy 10.3 NGFR PARP1
47 prolactin producing pituitary tumor 10.3 NGF NTRK1
48 charcot-marie-tooth disease and deafness 10.3 MPZ NTF3 PMP22
49 wallerian degeneration 10.3 CNTF MPZ VEGFA
50 ocular dominance 10.2 NGF NGFR NTF3

Graphical network of the top 20 diseases related to Diabetic Neuropathy:



Diseases related to Diabetic Neuropathy
Sources

Symptoms & Phenotypes for Diabetic Neuropathy

About this section

UMLS symptoms related to Diabetic Neuropathy:


neuralgia, sciatica

MGI Mouse Phenotypes related to Diabetic Neuropathy:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.47 GDNF AKR1B1 CNTF INS ACE VEGFA
2 homeostasis/metabolism MP:0005376 10.39 ACE AKR1B1 CNTF INS EPO TRPV1
3 growth/size/body region MP:0005378 10.38 ACE GDNF AKR1B1 INS TRPV1 VEGFA
4 immune system MP:0005387 10.34 GDNF CNTF INS EPO ACE TRPV1
5 mortality/aging MP:0010768 10.34 GDNF AKR1B1 INS EPO ACE VEGFA
6 cellular MP:0005384 10.29 EPO GDNF CNTF VEGFA TRPV1 NGFR
7 cardiovascular system MP:0005385 10.26 ACE GDNF EPO VEGFA TRPV1 NGFR
8 hematopoietic system MP:0005397 10.26 ACE GDNF CNTF EPO VEGFA MPZ
9 nervous system MP:0003631 10.21 GDNF CNTF INS TRPV1 VEGFA MPZ
10 integument MP:0010771 10.18 INS EPO TRPV1 VEGFA NGF NGFR
11 muscle MP:0005369 10.14 GDNF CNTF INS EPO VEGFA NTF3
12 liver/biliary system MP:0005370 10 EPO ACE VEGFA TRPV1 NGFR INS
13 no phenotypic analysis MP:0003012 9.92 CNTF INS VEGFA TRPV1 NGF PARP1
14 normal MP:0002873 9.91 EPO VEGFA NTF3 NGF INS NGFR
15 renal/urinary system MP:0005367 9.85 ACE GDNF AKR1B1 INS TRPV1 VEGFA
16 reproductive system MP:0005389 9.61 ACE GDNF VEGFA MPZ NTF3 INS
17 vision/eye MP:0005391 9.32 AKR1B1 INS VEGFA NTF3 NGF NGFR
Sources

Drugs & Therapeutics for Diabetic Neuropathy

About this section

Drugs for Diabetic Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 468)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
2
AT-101 Approved, Investigational Phase 4,Phase 3 90141-22-3, 652-67-5 12597
3
Isosorbide Dinitrate Approved, Investigational Phase 4,Phase 3 87-33-2 6883
4
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10102-43-9 145068 160954
5
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
6
Aztreonam Approved Phase 4 78110-38-0 5362041 5742832
7
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
8
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
9
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
10
Metronidazole Approved Phase 4 443-48-1 4173
11
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
12
Piperacillin Approved Phase 4,Phase 3 66258-76-2 43672
13
Tazobactam Approved Phase 4,Phase 3 89786-04-9 123630
14
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 56-12-2 119
15
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 137-58-6 3676
16
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
17
Nabilone Approved, Investigational Phase 4,Phase 3 51022-71-0 5284592
18
Hydroxocobalamin Approved Phase 4,Phase 3,Not Applicable 13422-51-0 11953898 44475014
19
Ciprofloxacin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 85721-33-1 2764
20
Sulfamethoxazole Approved Phase 4,Not Applicable 723-46-6 5329
21
Trimethoprim Approved, Vet_approved Phase 4,Not Applicable 738-70-5 5578
22
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2 60142-96-3 3446
23
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
24
Tramadol Approved, Investigational Phase 4,Phase 3 27203-92-5 33741
25
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
26
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
27
Amitriptyline Approved Phase 4,Phase 2,Not Applicable 50-48-6 2160
28
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
29
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
30
Acetylcholine Approved Phase 4,Phase 2,Not Applicable 51-84-3 187
31
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
32
Indapamide Approved Phase 4 26807-65-8 3702
33
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
34
Alginic acid Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 9005-32-7
35
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
36
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
37
Cefoxitin Approved Phase 4 35607-66-0 441199
38
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
39
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 564-25-0 54671203
40
Fusidic Acid Approved, Investigational Phase 4 6990-06-3 3000226
41
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
42
Chlorhexidine Approved, Vet_approved Phase 4,Not Applicable 55-56-1 9552079 2713
43
Petrolatum Approved, Investigational Phase 4 8009-03-8
44
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
45
Sulbactam Approved Phase 4 68373-14-8
46 Sultamicillin Approved, Investigational Phase 4 76497-13-7
47
Vancomycin Approved Phase 4,Phase 3 1404-90-6 441141 14969
48
Codeine Approved, Illicit Phase 4,Phase 1 76-57-3 5284371
49
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
50
Saxagliptin Approved Phase 4 361442-04-8 11243969

Interventional clinical trials:

(show top 50) (show all 854)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy Unknown status NCT01770964 Phase 4 Pregabalin;placebo
2 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy Unknown status NCT00123136 Phase 4
3 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
4 Inspiratory Muscle Training in Patients With Autonomic Neuropathic Unknown status NCT00752440 Phase 4
5 Maggot Debridement Therapy Versus Conventional Dressing Therapy to Treat Diabetic Foot Ulcers Unknown status NCT02816749 Phase 4
6 A Comparative Efficacy Study of DermaPureâ„¢ to Treat Diabetic Foot Ulcers Unknown status NCT02081352 Phase 4
7 Efficacy and Safety of Garamycin® Sponge (Gentamicin-Collagen Sponge) in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Unknown status NCT01951768 Phase 4 Garamycin Sponge (Gentamicin-Collagen sponge);Systemic Antibiotic
8 Clinical Evaluation of the SNaP Wound Care System Unknown status NCT01113658 Phase 4
9 A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
10 Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
11 A Study on the Efficacy and Safety of Gabapentin in the Treatment of Patients With Painful Diabetic Neuropathy Completed NCT00644748 Phase 4 gabapentin
12 A Study to Compare Safety and Efficacy of Tramadol Hydrochloride/Acetaminophen With Gabapentin in Participants With Diabetic Neuropathy Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
13 Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
14 Alpha Lipoic Acid for Treatment of Diabetic Neuropathy Completed NCT02439879 Phase 4 Alpha lipoic acid
15 A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
16 Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) Completed NCT00322621 Phase 4 Duloxetine
17 Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies Completed NCT02842554 Phase 4 Drug Placebo Administration
18 Evaluation of Rocker sOles in Diabetis Completed NCT02891928 Phase 4
19 Evaluation of the Efficacy of Cesametâ„¢ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesametâ„¢ (nabilone)
20 Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain Completed NCT00266643 Phase 4 duloxetine hydrochloride
21 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
22 An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
23 Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
24 A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN) Completed NCT00156078 Phase 4 pregabalin
25 A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
26 Lovaza® and Microvascular Function in Type 2 Diabetes Completed NCT00931879 Phase 4 omega-3-ethyl esters;Placebo
27 Anodyne Therapy in Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
28 Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy Pain Completed NCT01089855 Phase 4 Carbamazepine
29 Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
30 PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs Completed NCT02249897 Phase 4 CHOLESTYRAMINE
31 A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
32 Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy Completed NCT00903851 Phase 4 Lidoderm
33 Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109) Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
34 A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP) Completed NCT02417935 Phase 4 Duloxetine;Pregabalin;Placebo
35 Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
36 Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
37 Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
38 Study of Oasis Ultra in Diabetic Foot Ulcers Completed NCT01835379 Phase 4
39 Efficacy of Administration of ACE-Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
40 Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP Completed NCT00407511 Phase 4 Pregabalin
41 The InsuPad in Daily Life Study - Effect of Local Heating on Postprandial Glucose Excursions Using the InsuPad Device Completed NCT01352767 Phase 4
42 Botulinum Toxin in Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
43 Renal Denervation in Diabetic Nephropathy Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
44 GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers Completed NCT02675855 Phase 4
45 Use of Santyl in Diabetic Foot Ulcers Completed NCT02581488 Phase 4
46 Diabetic Foot Ulcer Study on Topical Interventions Completed NCT02577900 Phase 4
47 GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds Completed NCT02260609 Phase 4
48 LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers Completed NCT02224742 Phase 4
49 Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis Completed NCT02123628 Phase 4 duration of the antibiotic therapy
50 Santyl Applications to Diabetic Foot Ulcers Completed NCT02111291 Phase 4

Search NIH Clinical Center for Diabetic Neuropathy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diabetic Neuropathy cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Diabetic Neuropathy:
Hematopoietic stem cells for limb ischemia and diabetic neuropathy
Embryonic/Adult Cultured Cells Related to Diabetic Neuropathy:
Peripheral blood-derived hematopoietic stem cells (family)
Sources

Genetic Tests for Diabetic Neuropathy

About this section
Sources

Anatomical Context for Diabetic Neuropathy

About this section

MalaCards organs/tissues related to Diabetic Neuropathy:

41
Skin, Bone, Testes, Endothelial, Bone Marrow, Spinal Cord, Heart
Sources

Publications for Diabetic Neuropathy

About this section

Articles related to Diabetic Neuropathy:

(show top 50) (show all 824)
# Title Authors Year
1
Cure of human diabetic neuropathy by HPLC validated bark extract of Onosma echioides L. root. ( 29629826 )
2018
2
Diabetic neuropathy and painful diabetic neuropathy: Cinderella complications in South East Asia. ( 29371725 )
2018
3
Single fiber F-waves compared with conventional surface F-waves, and their utility in detecting early diabetic neuropathy. ( 29975798 )
2018
4
Neuroprotective effect of duloxetine in a mouse model of diabetic neuropathy: Role of glia suppressing mechanisms. ( 29763613 )
2018
5
Comparison of peripheral nerve blockade characteristics between non-diabetic patients and patients suffering from diabetic neuropathy: a prospective cohort study. ( 29858510 )
2018
6
Adenosine monophosphate-activated protein kinase modulation by berberine attenuates mitochondrial deficits and redox imbalance in experimental diabetic neuropathy. ( 29273519 )
2018
7
Cerebral Biochemical Effect of Pregabalin in Patients with Painful Diabetic Neuropathy: A Randomized Controlled Trial. ( 29951977 )
2018
8
Feasibility and effectiveness of electrochemical dermal conductance measurement for the screening of diabetic neuropathy in primary care. DECODING Study (Dermal Electrochemical Conductance in Diabetic Neuropathy). Rationale and design. ( 29768354 )
2018
9
Hearing Loss in Type 2 Diabetes in Association with Diabetic Neuropathy. ( 29433858 )
2018
10
Tanshinone IIA Improves Painful Diabetic Neuropathy by Suppressing the Expression and Activity of Voltage-Gated Sodium Channel in Rat Dorsal Root Ganglia. ( 29388177 )
2018
11
Fluoxetine pretreatment enhances neurogenic, angiogenic and immunomodulatory effects of MSCs on experimentally induced diabetic neuropathy. ( 29687216 )
2018
12
Neuropathic pain drives anxiety behavior in mice, results consistent with anxiety levels in diabetic neuropathy patients. ( 29922743 )
2018
13
Transcriptome analysis of dorsal root ganglia's diabetic neuropathy reveals mechanisms involved in pain and regeneration. ( 29750992 )
2018
14
Phloretin either alone or in combination with duloxetine alleviates the STZ-induced diabetic neuropathy in rats. ( 29635891 )
2018
15
The H-Reflex as a Biomarker for Spinal Disinhibition in Painful Diabetic Neuropathy. ( 29362940 )
2018
16
Diabetic neuropathy differs between type 1 and type 2 diabetes Insights from magnetic resonance neurography. ( 29443416 )
2018
17
Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets. ( 29966615 )
2018
18
Peripheral Glial Cells in the Development of Diabetic Neuropathy. ( 29770116 )
2018
19
Altered Achilles tendon function during walking in people with diabetic neuropathy: implications for metabolic energy saving. ( 29420151 )
2018
20
Gene therapy with the angiogenic neuropeptide secretoneurin ameliorates experimental diabetic neuropathy. ( 29913555 )
2018
21
Bone marrow-derived mesenchymal stem/stromal cells reverse the sensorial diabetic neuropathy via modulation of spinal neuroinflammatory cascades. ( 29933760 )
2018
22
Pharmacodynamics and Pharmacokinetics of Lidocaine in a Rodent Model of Diabetic Neuropathy. ( 29251644 )
2018
23
The correlation between obstructive sleep apnea and diabetic neuropathy: A meta-analysis. ( 29728306 )
2018
24
Nebivolol, a I^-blocker abrogates streptozotocin-induced behavioral, biochemical, and neurophysiological deficit by attenuating oxidative-nitrosative stress: a possible target for the prevention of diabetic neuropathy. ( 29322226 )
2018
25
Expression of macrophage migration inhibitory factor in footpad skin lesions with diabetic neuropathy. ( 29690804 )
2018
26
[EXPRESS] Auricular vagus nerve stimulation enhances central serotonergic function and inhibits diabetic neuropathy development in Zucker fatty rats. ( 29921169 )
2018
27
Preclinical assessment of utility of M6S for multimodal acute and chronic pain treatment in diabetic neuropathy. ( 29191644 )
2018
28
Diabetic Neuropathy - situational analysis in Pakistan. ( 29371708 )
2018
29
Neuroprotective and antinociceptive effects of rosemary (Rosmarinus officinalis L.) extract in rats with painful diabetic neuropathy. ( 29754274 )
2018
30
Axonal transport in a peripheral diabetic neuropathy model: sex-dimorphic features. ( 29351809 )
2018
31
Diabetic Neuropathy: A Position Statement by the American Diabetes Association. ( 27999003 )
2017
32
Postherpetic neuralgia, diabetic neuropathy, and trigeminal neuralgia - Chronic peripheral neuropathic pain in 58,480 rural Italian primary care patients. ( 29026761 )
2017
33
Improving pain control in diabetic neuropathy. ( 29139278 )
2017
34
Functional recovery upon human dental pulp stem cell transplantation in a diabetic neuropathy rat model. ( 28864291 )
2017
35
Treatment of mild to moderate carpal tunnel syndrome in patients with diabetic neuropathy using low level laser therapy versus ultrasound controlled comparative study. ( 28856107 )
2017
36
Diabetic Neuropathy Evaluated by a Novel Device: Sural Nerve Conduction Is Associated with Glycemic Control and Ankle-Brachial Pressure Index in Japanese Patients with Diabetes. ( 28861044 )
2017
37
Longitudinal study of neuropathy, microangiopathy, and autophagy in sural nerve: Implications for diabetic neuropathy. ( 28828222 )
2017
38
Morin exerts neuroprotection via attenuation of ROS induced oxidative damage and neuroinflammation in experimental diabetic neuropathy. ( 29193444 )
2017
39
New understanding of mechanisms of painful diabetic neuropathy: A path to prevention and better treatment? ( 29913910 )
2017
40
Diagnostic utility of corneal confocal microscopy and intra-epidermal nerve fibre density in diabetic neuropathy. ( 28719619 )
2017
41
Association between MTHFR variant and diabetic neuropathy. ( 29222982 )
2017
42
Neural Mobilization Attenuates Mechanical Allodynia and Decreases Proinflammatory Cytokine Concentrations in Rats With Painful Diabetic Neuropathy. ( 29309710 )
2017
43
Diphenyleneiodonium Mitigates Bupivacaine-Induced Sciatic Nerve Damage in a Diabetic Neuropathy Rat Model by Attenuating Oxidative Stress. ( 28682956 )
2017
44
Ankle-brachial index and diabetic neuropathy: study of 225 patients. ( 28813083 )
2017
45
Quantification of Quercetin Obtained from Allium cepa Lam. Leaves and its Effects on Streptozotocin-induced Diabetic Neuropathy. ( 28827972 )
2017
46
A new solvate of epalerstat, a drug for diabetic neuropathy. ( 28932450 )
2017
47
mGluR2/3 activation of the SIRT1 axis preserves mitochondrial function in diabetic neuropathy. ( 29296613 )
2017
48
Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study. ( 28858986 )
2017
49
Long-Term Outcomes in the Management of Painful Diabetic Neuropathy. ( 28065184 )
2017
50
Transient receptor potential ankyrin 1 (TRPA1) ion channel in the pathophysiology of peripheral diabetic neuropathy. ( 29913916 )
2017
Sources

Variations for Diabetic Neuropathy

About this section
Sources

Expression for Diabetic Neuropathy

About this section
Search GEO for disease gene expression data for Diabetic Neuropathy.
Sources

Pathways for Diabetic Neuropathy

About this section

Pathways related to Diabetic Neuropathy according to KEGG:

37
# Name Kegg Source Accession
1 AGE-RAGE signaling pathway in diabetic complications hsa04933

Pathways related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
PEDF Induced Signaling 64
Show member pathways
 13.48 CNTF EPO GDNF INS NGF NGFR
2
TGF-Beta Pathway 64
Show member pathways
 13.29 EPO INS NGF NGFR NTF3 NTRK1
3
p70S6K Signaling 64
Show member pathways
 12.81 ACE INS NGF NGFR NTF3 NTRK1
4
PI3K-Akt signaling pathway 37
Show member pathways
 12.63 EPO INS NGF NGFR NTF3 NTRK1
5
MAPK signaling pathway 1 37
12.51 INS NGF NGFR NTF3 NTRK1 VEGFA
6
Ras signaling pathway 37
Show member pathways
 12.44 INS NGF NGFR NTF3 NTRK1 VEGFA
7
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.42 NGF NTRK1 PARP1 TRPV1 VEGFA
8
Neuroscience 4
12.39 NGF NGFR NTRK1 SCN9A
9
Brain-Derived Neurotrophic Factor (BDNF) signaling pathway 1
11.86 NGF NGFR NTF3 NTRK1
10
Guidance Cues and Growth Cone Motility 64
11.79 NGF NGFR NTRK1
11
HIF-1 signaling pathway 37
11.7 EPO INS VEGFA
12
p75(NTR)-mediated signaling 1
Show member pathways
 11.47 NGF NGFR NTF3
13
Neurotrophic factor-mediated Trk receptor signaling 1
Show member pathways
 11.24 NGF NGFR NTF3 NTRK1